您现在的位置是:f s o s h h u j 1 t w i c c a z h i 8 s s z 8 t s a e > Fashion
【will nail salons do nails with fungus】ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting
f s o s h h u j 1 t w i c c a z h i 8 s s z 8 t s a e2024-09-29 12:28:48【Fashion】1人已围观
简介Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™)AU will nail salons do nails with fungus
Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™)
AUSTIN,will nail salons do nails with fungus Texas, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq:
PSTV
) (the “Company”), today announced that its abstract regarding lead investigational drug, Rhenium NanoLiposomes (RNL™), was accepted to the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually on November 19-21, 2020.
“We are looking forward to updating the medical community on the latest data from our ReSPECT™ Phase 1 trial,” said Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. “Until then, we will continue to focus on completing ReSPECT trial enrollment and the chemistry and manufacturing controls required to advance RNL to the next step of clinical development.”
The Company will be providing a detailed interim safety, tolerability, dosing and efficacy data from its ReSPECT Phase 1 clinical trial of a novel radiotherapy, RNL, in adults with recurrent glioblastoma (GBM) after standard surgical, radiation, and chemotherapy treatment. GBM is a rare, incurable and fatal disease with a median survival of about nine months following recurrence despite the current standard of care.
ReSPECT is currently supported by an award from the National Cancer Institute. The Company plans to complete enrollment in the Phase 1 trial by the end of 2020 and in parallel will utilize its recently awarded U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations to determine the next steps for the program.
Additional details about the ReSPECT trial are available at clinicaltrials.gov (
NCT01906385
).
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at
plustherapeutics.com
and
respect-trials.com
.
About The Society for Neuro-Oncology
The Society for Neuro-Oncology exists to advance multi-disciplinary brain tumor research, education, and collaboration to drive discovery and improve patient care. Over 2,600 neuro-oncology professionals are anticipated to register for the 25
th
Annual Scientific Meeting and Education Day being held virtually on November 19-21, 2020. More information can be found at
soc-neuro-onc.org
.
Story continues
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company’s potential to develop drug candidates currently in its product pipeline; and the Company’s potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
View comments
很赞哦!(468)
相关文章
- SponsorsOne Assembles Management Dream Team For Craft Alcohol Product Development, Branding, Marketing, Sales and Distribution
- GLOBAL MARKETS-Stocks pare losses but economic concerns linger
- Here’s What Cathay General Bancorp’s (NASDAQ:CATY) P/E Ratio Is Telling Us
- Starting in 2019, You Won't Get a $7500 Tax Credit on a New Tesla
- Sherwin-Williams (SHW): Strong Growth And Abundant Potential
- BRIEF-Hylink Digital Solution In Framework Agreement With Data Service Firm TalkingData
- Paul Weiss, Partner Promotions and the Path to Diversity in Big Law
- Is Intek Group S.p.A.’s (BIT:IKG) Balance Sheet A Threat To Its Future?
- AP Top Extended Financial Headlines at 9:52 p.m. EST
- Do Insiders Own Lots Of Shares In PSL Limited (NSE:PSL)?
热门文章
站长推荐
CORRECTED-Fed's Evans says U.S. should support workers who lose pay if coronavirus worsens
Are Casta Diva Group S.p.A.’s (BIT:CDG) Interest Costs Too High?
VEGOILS-Market factors to watch Jan 2
These bonds are still offering investors positive yields
Aligos Therapeutics Appoints Lesley Ann Calhoun as Chief Financial Officer
EU to send inspectors to Poland over suspect meat
Austria sees likelihood of hard Brexit -foreign minister
MOVES-JPMorgan brings back China healthcare investment banker to boost coverage
友情链接
- ‘Futurama’ Drama Resolved: John DiMaggio Returns for New Season on Hulu
- Psych Yourself Up for Your Next Job Interview
- Can We See Significant Institutional Ownership On The Ceconomy AG (FRA:CEC) Share Register?
- Amazon.com Rises 3%
- Will Adobe Inc.’s (NASDAQ:ADBE) Earnings Grow Over The Next Few Years?
- USD/JPY Keeps Rising Despite Chunky Japanese Profits
- Fatalities on commercial passenger aircraft rise in 2018
- Romney attacks Trump, saying he causes dismay around the world
- New Study Confirms High Inter-Observer Agreement Using the WATS3D Biopsy for Evaluation of Esophageal Pre-Cancer
- BRIEF-Vpower Group International Says Power Plant Commences Commercial Operation